Advanced drug delivery systems that target the vascular endothelium

被引:129
作者
Ding, BS [1 ]
Dziubla, T
Shuvaev, VV
Muro, S
Muzykantov, VR
机构
[1] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Targeted Therapeut Program, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA
关键词
D O I
10.1124/mi.6.2.7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Targeted drug delivery to endothelial cells lining the vascular lumen will provide effective, precise and safe therapeutic interventions for treatment of diverse disease conditions. Rational design of such drug delivery systems (DDS) includes the following intertwined tasks: 1) selection of proper target determinants on endothelial surfaces, such as cell adhesion molecules, ectopeptidases, or caveolar antigens, 2) production of affinity ligands useful for targeting, such as affinity peptides, antibodies, or their fragments,- 3) selection and adopting of suitable delivery vehicles (such as liposomes or polymer nanocarriers); and 4) formulation of DDS with optimal targeting and therapeutic features. Important therapeutic features of DDS include: 1) sufficient targeting effectiveness, circulation time, and safety (i.e., lack of systemic and local adverse effects),- 2) precise subcellular localization of drugs targeted to endothelial cells; and 3) adequate amplitude, kinetics, and duration of effects. This review utilizes examples of DDS-mediated interventions in vascular inflammation, oxidative stress, and thrombosis and analyzes them in an attempt to create design parameters that best regulate the pharmacological and therapeutic features of DDS that target endothelial cells.
引用
收藏
页码:98 / 112
页数:15
相关论文
共 97 条
[91]   Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells [J].
Vinogradov, SV ;
Bronich, TK ;
Kabanov, AV .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (01) :135-147
[92]   EVIDENCE FOR ENDOCYTOSIS OF E-SELECTIN IN HUMAN ENDOTHELIAL-CELLS [J].
VONASMUTH, EJU ;
SMEETS, EE ;
GINSEL, LA ;
ONDERWATER, JJM ;
LEEUWENBERG, JFM ;
BUURMAN, WA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (10) :2519-2526
[93]   Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice [J].
Wang, YMF ;
Tsirka, SE ;
Strickland, S ;
Stieg, PE ;
Soriano, SG ;
Lipton, SA .
NATURE MEDICINE, 1998, 4 (02) :228-231
[94]   Putrescine-modified catalase with preserved enzymatic activity exhibits increased permeability at the blood-nerve and blood-brain barriers [J].
Wengenack, TM ;
Curran, GL ;
Olson, EE ;
Poduslo, JF .
BRAIN RESEARCH, 1997, 767 (01) :128-135
[95]   The 'right' size in nanobiotechnology [J].
Whitesides, GM .
NATURE BIOTECHNOLOGY, 2003, 21 (10) :1161-1165
[96]   Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells [J].
Wiewrodt, R ;
Thomas, AP ;
Cipelletti, L ;
Christofidou-Solomidou, M ;
Weitz, DA ;
Feinstein, SI ;
Schaffer, D ;
Albelda, SM ;
Koval, M ;
Muzykantov, VR .
BLOOD, 2002, 99 (03) :912-922
[97]  
Wong S.S., 1991, CHEM PROTEIN CONJUGA